Chapter 10 : BCG and New Vaccines against Tuberculosis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

BCG and New Vaccines against Tuberculosis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817138/9781555815134_Chap10-1.gif /docserver/preview/fulltext/10.1128/9781555817138/9781555815134_Chap10-2.gif


Several tuberculosis vaccines have been shown to reduce the risk of disease and death due to tuberculosis in humans, but only one is used in global immunization programs: bacillus Calmette-Guerin (BCG). The development of new tuberculosis vaccines has been informed by evolving data on the natural history of tuberculosis, by new data on the immunology of infection with and immunization against , by reanalysis of the role of nontuberculous mycobacteria (NTM) in protection against tuberculosis, by a clearer understanding of the benefits and risks of BCG, and by molecular techniques that have permitted identification of immunodominant antigens of and new methods of antigen delivery. This chapter talks about tuberculosis in children, older children, adults, elderly, and immunocompromised hosts, health care providers and other International travelers. At least partial immune protection from tuberculosis disease results from prior mycobacterial infection, whether naturally acquired or vaccine induced. The chapter discusses mechanisms of immune control of tuberculosis, and talks about BCG vaccine. Immunization with BCG induces a mild systemic infection in healthy hosts. It has been shown that immune responses to BCG are impaired in infants with human immunodeficiency virus (HIV) infection. The efficacy of BCG against tuberculosis is described. The favorable and unfavorable characteristics of BCG are summarized. There is wide consensus that additional tuberculosis vaccine development should focus on identifying a booster vaccine to follow BCG immunization, or on developing a completely novel two-vaccine booster regimen.

Citation: Lahey T, Reyn C. 2011. BCG and New Vaccines against Tuberculosis, p 162-181. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817138.ch10
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Abebe, F.,, and G. Bjune. 2009. The protective role of antibody responses during Mycobacterium tuberculosis infection. Clin. Exp. Immunol. 157: 235243.
2. Abruzzi, W. A., Jr.,, and R. J. Hummel. 1953. Tuberculosis: incidence among American medical students, prevention and control and the use of BCG. N. Engl. J. Med. 248: 722729.
3. Agger, E. M.,, K. Weldingh,, A. W. Olsen,, I. Rosenkrands,, and P. Andersen. 2002. Specific acquired resistance in mice immunized with killed mycobacteria. Scand. J. Immunol. 56: 443447.
4. Alderson, M. R.,, T. Bement,, C. H. Day,, L. Zhu,, D. Molesh,, Y. A. Skeiky,, R. N. Coler,, D. M. Lewinsohn,, S. G. Reed,, and S. G. Dillon. 2000. Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4+ T cells. J. Exp. Med. 191: 551559.
5. American Academy of Pediatrics. 2003. Report of the Committee on Infectious Diseases. American Academy of Pediatrics, Elk Grove, IL.
6. Andersen, P. 2001. TB vaccines: progress and problems. Trends Immunol. 22: 160168.
7. Aronson, J. D. 1948. Protective vaccination against tuberculosis with special reference to BCG vaccination. Am. Rev. Tuberc. 58: 255281.
8. Aronson, N. E.,, M. Santosham,, G. W. Comstock,, R. S. Howard,, L. H. Moulton,, E. R. Rhoades,, and L. H. Harrison. 2004. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 291: 20862091.
9. Azzopardi, P.,, C. M. Bennett,, S. M. Graham,, and T. Duke. 2009. Bacille Calmette-Guerin vaccine-related disease in HIV-infected children: a systematic review. Int. J. Tuberc. Lung Dis. 13: 13311344.
10. Badri, M.,, W. Wilson,, and R. Wood. 2002. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359: 20592064.
11. Barbosa, T.,, S. Arruda,, B. D. Fernandes,, L. P. Carvalho,, S. Cardoso,, S. Cunha,, M. L. Barreto,, S. M. Pereira,, L. C. Rodrigues,, and M. Barral-Netto. 2003. BCG (Bacille of Calmette-Guerin) revaccination leads to improved in vitro IFN-gamma response to mycobacterial antigen independent of tuberculin sensitization in Brazilian school-age children. Vaccine 21: 21522160.
12. Barclay, W. R.,, W. M. Busey,, D. W. Dalgard,, R. C. Good,, B. W. Janicki,, J. E. Kasik,, E. Ribi,, C. E. Ulrich,, and E. Wolinsky. 1973. Protection of monkeys against airborne tuberculosis by aerosol vaccination with Bacillus Calmette-Guerin. Am. Rev. Respir. Dis. 107: 351358.
13. Barker, L. F.,, M. J. Brennan,, P. K. Rosenstein,, and J. C. Sadoff. 2009. Tuberculosis vaccine research: the impact of immunology. Curr. Opin. Immunol. 21: 331338.
14. Barreto, M. L.,, S. S. Cunha,, S. M. Pereira,, B. Genser,, M. A. Hijjar,, M. Yury Ichihara,, S. C. de Brito,, I. Dourado,, A. Cruz,, C. Santa’Ana,, and L. C. Rodrigues. 2005. Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil. Int. J. Tuberc. Lung Dis. 9: 11711173.
15. Behr, M. A. 2001. Correlation between BCG genomics and protective efficacy. Scand. J. Infect. Dis. 33: 249252.
16. Bendiner, E. 1992. Albert Calmette: a vaccine and its vindication. Hosp. Pract. (Off. Ed.) 27: 113116, 119–122, 125 passim.
17. Besnard, M.,, S. Sauvion,, C. Offredo,, J. Gaudelus,, J. L. Gaillard,, F. Veber,, and S. Blanche. 1993. Bacillus Calmette-Guerin infection after vaccination of human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 12: 993997.
18. Beyazova, U.,, S. Rota,, C. Cevheroglu,, and T. Karsligil. 1995. Humoral immune response in infants after BCG vaccination. Tuberc. Lung Dis. 76: 248253.
19. Black, G. F.,, B. A. Thiel,, M. O. Ota,, S. K. Parida,, R. Adegbola,, W. H. Boom,, H. M. Dockrell,, K. L. Franken,, A. H. Friggen,, P. C. Hill,, M. R. Klein,, M. K. Lalor,, H. Mayanja,, G. Schoolnik,, K. Stanley,, K. Weldingh,, S. H. Kaufmann,, G. Walzl,, and T. H. Ottenhoff. 2009. Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin. Vaccine Immunol. 16: 12031212.
20. Boelaert, J. R.,, S. J. Vandecasteele,, R. Appelberg,, and V. R. Gordeuk. 2007. The effect of the host’s iron status on tuberculosis. J. Infect. Dis. 195: 17451753.
21. Brandt, L.,, J. F. Cunha,, A. W. Olsen,, B. Chilima,, P. Hirsch,, R. Appleberg,, and P. Andersen. 2002. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 70: 672678.
22. Brandt, L.,, Y. A. Skeiky,, M. R. Alderson,, Y. Lobet,, W. Dale-mans,, O. C. Turner,, R. J. Basaraba,, A. A. Izzo,, T. M. Lasco,, P. L. Chapman,, S. G. Reed,, and I. M. Orme. 2004. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. 72: 66226632.
23. Brennan, M. J.,, and U. Fruth. 2002. Global forum on TB vaccine research and development. World Health Organization, June 7–8, 2001, Geneva. Tuberculosis (Edinburgh) 81: 365368.
24. Brewer, M. A.,, K. M. Edwards,, P. S. Palmer,, and H. P. Hinson. 1994. Bacille Calmette-Guerin immunization in normal healthy adults. J. Infect. Dis. 170: 476479.
25. Brewer, T. F.,, S. J. Heymann,, S. M. Krumplitsh,, M. E. Wilson,, G. A. Colditz,, and H. V. Fineberg. 2001. Strategies to decrease tuberculosis in US homeless populations. JAMA 286: 834842.
26. Caglayan, S.,, O. Yegin,, K. Kayran,, N. Timocin,, E. Kasirga,, and M. Gun. 1987. Is medical therapy effective for regional lymphadenitis following BCG vaccination? Am. J. Dis. Child. 141: 12131214.
27. Centers for Disease Control and Prevention. 1996. The role of BCG vaccine in the prevention and control of tuberculosis in the United States: a joint statement by the Advisory Committee for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Morb. Mortal. Wkly. Rep. 45: 118.
28. Chandra, R. N. P. 1977. Nutrition, Immunity and Infection: Mechanisms of Interactions. Plenum Press, New York, NY.
29. Chen, C. Y.,, D. Huang,, R. C. Wang,, L. Shen,, G. Zeng,, S. Yao,, Y. Shen,, L. Halliday,, J. Fortman,, M. McAllister,, J. Estep,, R. Hunt,, D. Vasconcelos,, G. Du,, S. A. Porcelli,, M. H. Larsen,, W. R. Jacobs, Jr.,, B. F. Haynes,, N. L. Letvin,, and Z. W. Chen. 2009. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS 5 (4): e1000392.
30. Chen, L.,, J. Wang,, A. Zganiacz,, and Z. Xing. 2004. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun. 72: 238246.
31. Clark, S.,, M. L. Cross,, A. Smith,, P. Court,, J. Vipond,, A. Nadian,, R. G. Hewinson,, H. K. Batchelor,, Y. Perrie,, A. Williams,, F. E. Aldwell,, and M. A. Chambers. 2008. Assessment of different formulations of oral Mycobacterium bovis Bacille Calmette-Guerin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M. bovis. Vaccine 26: 57915797.
32. Clemens, J. D.,, J. J. Chuong,, and A. R. Feinstein. 1983. The BCG controversy: a methodological and statistical reappraisal. JAMA 249: 23622369.
33. Cobelens, F. G.,, H. van Deutekom,, I. Draayer-Jansen,, A. C. Schepp-Beelen,, P. J. van Gerven,, R. P. van Kessel,, and M. E. Mensen. 2000. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet 356: 461465.
34. Colditz, G. A.,, C. S. Berkey,, F. Mosteller,, T. F. Brewer,, M. E. Wilson,, E. Burdick,, and H. V. Fineberg. 1995. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96: 2935.
35. Colditz, G. A.,, T. F. Brewer,, C. S. Berkey,, M. E. Wilson,, E. Burdick,, H. V. Fineberg,, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 271: 698702.
36. Constant, P.,, F. Davodeau,, M. A. Peyrat,, Y. Poquet,, G. Puzo,, M. Bonneville,, and J. J. Fournie. 1994. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 264: 267270.
37. Cross, M. L.,, M. R. Lambeth,, Y. Coughlan,, and F. E. Ald-well. 2007. Oral vaccination of mice with lipid-encapsulated Mycobacterium bovis BCG: effect of reducing or eliminating BCG load on cell-mediated immunity. Vaccine 25: 12971303.
38. Cunha, S. S.,, N. Alexander,, M. L. Barreto,, E. S. Pereira,, I. Dourado,, F. Maroja Mde,, Y. Ichihara,, S. Brito,, S. Pereira,, and L. C. Rodrigues. 2008. BCG revaccination does not protect against leprosy in the Brazilian Amazon: a cluster randomised trial. PLoS Negl. Trop. Dis. 2: e167.
39. Day, C. L.,, N. Mkhwanazi,, S. Reddy,, Z. Mncube,, M. van der Stok,, P. Klenerman,, and B. D. Walker. 2008. Detection of poly-functional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J. Infect. Dis. 197: 990999.
40. Dorer, D. E.,, W. Czepluch,, M. R. Lambeth,, A. C. Dunn,, C. Reitinger,, F. E. Aldwell,, and A. D. McLellan. 2007. Lymphatic tracing and T cell responses following oral vaccination with live Mycobacterium bovis (BCG). Cell. Microbiol. 9: 544553.
41. Edwards, L. B.,, and C. E. Palmer. 1968. Identification of the tuberculous-infected by skin tests. Ann. N. Y. Acad. Sci. 154: 140148.
42. Edwards, M. L.,, J. M. Goodrich,, D. Muller,, A. Pollack,, J. E. Ziegler,, and D. W. Smith. 1982. Infection with Mycobacterium avium-intracellulare and the protective effects of Bacille Calmette-Guerin. J. Infect. Dis. 145: 733741.
43. Eisenhut, M.,, S. Paranjothy,, I. Abubakar,, S. Bracebridge,, M. Lilley,, R. Mulla,, K. Lack,, D. Chalkley,, and M. McEvoy. 2009. BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. Vaccine 27: 61166120.
44. Fairchok, M. P.,, J. H. Rouse,, and S. L. Morris. 1995. Age-dependent humoral responses of children to mycobacterial antigens. Clin. Diagn. Lab. Immunol. 2: 443447.
45. Ferguson, R. G.,, and A. B. Simes. 1949. BCG vaccination of infant Indians in Saskatchewan. Tubercle 30: 511.
46. Fine, P. E.,, I. A. Carneiro,, J. B. Milstien,, and C. J. Clements. 1999. Issues Relating to the Use of BCG in Immunization Programs: a Discussion Document. Department of Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
47. Fine, P. E. M. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 13391345.
48. Flahiff, E. W. 1939. The occurrence of tuberculosis in persons who failed to react to tuberculin, and in persons with positive tuberculin reaction. Am. J. Epidemiol. 30 (Section B): 6974.
49. Forbes, E. K.,, C. Sander,, E. O. Ronan,, H. McShane,, A. V. Hill,, P. C. Beverley,, and E. Z. Tchilian. 2008. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J. Immunol. 181: 49554964.
50. Glynn, J. R.,, J. Murray,, A. Bester,, G. Nelson,, S. Shearer,, and P. Sonnenberg. 2010. High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis. J. Infect. Dis. 201: 704711.
51. Golub, J. E.,, V. Saraceni,, S. C. Cavalcante,, A. G. Pacheco,, L. H. Moulton,, B. S. King,, A. Efron,, R. D. Moore,, R. E. Chaisson,, and B. Durovni. 2007. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 21: 14411448.
52. Goraya, J. S.,, and V. S. Virdi. 2001. Treatment of Calmette-Guerin bacillus adenitis: a metaanalysis. Pediatr. Infect. Dis. J. 20: 632634.
53. Grant, A. D.,, S. Charalambous,, K. L. Fielding,, J. H. Day,, E. L. Corbett,, R. E. Chaisson,, K. M. De Cock,, R. J. Hayes,, and G. J. Churchyard. 2005. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 293: 27192725.
54. Grode, L.,, P. Seiler,, S. Baumann,, J. Hess,, V. Brinkmann,, A. Nasser Eddine,, P. Mann,, C. Goosmann,, S. Bandermann,, D. Smith,, G. J. Bancroft,, J. M. Reyrat,, D. van Soolingen,, B. Raupach,, and S. H. Kaufmann. 2005. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Investig. 115: 24722479.
55. Gutierrez, M. G.,, S. S. Master,, S. B. Singh,, G. A. Taylor,, M. I. Colombo,, and V. Deretic. 2004. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119: 753766.
56. Haile, M.,, B. Hamasur,, T. Jaxmar,, D. Gavier-Widen,, M. A. Chambers,, B. Sanchez,, U. Schroder,, G. Kallenius,, S. B. Svenson,, and A. Pawlowski. 2005. Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice. Tuberculosis (Edinburgh) 85: 107114.
57. Haile, M.,, U. Schroder,, B. Hamasur,, A. Pawlowski,, T. Jaxmar,, G. Kallenius,, and S. B. Svenson. 2004. Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis. Vaccine 22: 14981508.
58. Hanrahan, C. F.,, J. E. Golub,, L. Mohapi,, N. Tshabangu,, T. Modisenyane,, R. E. Chaisson,, G. E. Gray,, J. A. McIntyre,, and N. A. Martinson. 2010. BMI and risk of tuberculosis and death: a prospective cohort of HIV-infected adults from South Africa. AIDS 24: 15011508.
59. Harries, A. D.,, N. J. Hargreaves,, J. Kemp,, A. Jindani,, D. A. Enarson,, D. Maher,, and F. M. Salanponi. 2001. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet 357: 15191523.
60. Harris, J.,, S. A. De Haro,, S. S. Master,, J. Keane,, E. A. Roberts,, M. Delgado,, and V. Deretic. 2007. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity 27: 505517.
61. Hart, P. D.,, J. A. Armstrong,, C. A. Brown,, and P. Draper. 1972. Ultrastructural study of the behavior of macrophages toward parasitic mycobacteria. Infect. Immun. 5: 803807.
62. Hart, P. D.,, and I. Sutherland. 1977. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br. Med. J. 2: 293295.
63. Hawkridge, A.,, M. Hatherill,, F. Little,, M. A. Goetz,, L. Barker,, H. Mahomed,, J. Sadoff,, W. Hanekom,, L. Geiter,, and G. Hussey. 2008. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ 337: a2052.
64. Hersh, A. L.,, M. Tala-Heikkilä,, E. Tala,, A. N. A. Tosteson,, and C. F. von Reyn. 2002. A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guerin in Finland. Int. J. Tuberc. Lung Dis. 7: 2229.
65. Hesseling, A. C.,, M. F. Cotton,, C. Fordham von Reyn,, S. M. Graham,, R. P. Gie,, and G. D. Hussey. 2008. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int. J. Tuberc. Lung Dis. 12: 13761379.
66. Hesseling, A. C.,, B. J. Marais,, R. P. Gie,, H. S. Schaaf,, P. E. Fine,, P. Godfrey-Faussett,, and N. Beyers. 2007. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 25: 1418.
67. Hesseling, A. C.,, H. S. Schaaf,, W. A. Hanekom,, N. Beyers,, M. F. Cotton,, R. P. Gie,, B. J. Marais,, P. van Helden,, and R. M. Warren. 2003. Danish bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin. Infect. Dis. 37: 12261233.
68. Hoft, D. F.,, A. Blazevic,, G. Abate,, W. A. Hanekom,, G. Kaplan,, J. H. Soler,, F. Weichold,, L. Geiter,, J. C. Sadoff,, and M. A. Horwitz. 2008. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J. Infect. Dis. 198: 14911501.
69. Hoft, D. F.,, R. M. Brown,, and R. B. Belshe. 2000. Mucosal Bacille Calmette Guerin vaccination of humans inhibits delayed type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon gamma responses. Clin. Infect. Dis. 30 (Suppl. 3): S217S222.
70. Hoft, D. F.,, E. B. Kemp,, O. Marinaro,, H. Cruz,, J. R. Kiyono,, J. T. McGhee,, T. W. Belisle,, J. P. Miller,, and R. B. Belshe. 1999. A double-blind, placebo-controlled study of Mycobacterium-specific human immune responses induced by intradermal bacille Calmette-Guérin vaccination. J. Lab. Clin. Med. 134: 244252.
71. Hoft, D. F.,, and J. M. Tennant. 1999. Persistence and boosting of Bacille Calmette-Guérin-induced delayed-type hypersensitivity. Ann. Intern. Med. 131: 3236.
72. Horsburgh, C. R. 2000. A large, simple trial of a tuberculosis vaccine. Clin. Infect. Dis. 30 (Suppl. 3): S213216.
73. Horsburgh, Jr. C. R., 2004. Priorities for the treatment of latent tuberculosis infection in the United States. N. Engl. J. Med. 350: 20602067.
74. Horsburgh, Jr., C. R.,, M. O’Donnell,, S. Chamblee,, J. L. Moreland,, J. Johnson,, B. J. Marsh,, M. Narita,, L. S. Johnson,, and C. F. von Reyn. 2010. Revisiting rates of reactivation tuberculosis: a population-based approach. Am. J. Respir. Crit. Care Med. 182: 420425.
75. Horwitz, M. A.,, and G. Harth. 2003. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. 71: 16721679.
76. Horwitz, M. A.,, G. Harth,, B. J. Dillon,, and S. Maslesa-Galic. 2006. Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity. Vaccine 24: 443451.
77. Jeon, C. Y.,, and M. B. Murray. 2008. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 5: e152.
78. Jeyanathan, M.,, J. Mu,, S. McCormick,, D. Damjanovic,, C. L. Small,, C. R. Shaler,, K. Kugathasan,, and Z. Xing. Murine airway luminal antituberculosis memory CD8 T cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment. Am. J. Respir. Crit. Care Med. 181: 862872.
79. Johnson, J. L.,, A. Okwera,, D. L. Hom,, H. Mayanja,, C. Mutuluuza Kityo,, P. Nsubuga,, J. G. Nakibali,, A. M. Loughlin,, H. Yun,, P. N. Mugyenyi,, A. Vernon,, R. D. Mugerwa,, J. J. Ellner,, and C. C. Whalen. 2001. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 15: 21372147.
80. Joosten, S. A.,, K. E. van Meijgaarden,, P. C. van Weeren,, F. Kazi,, A. Geluk,, N. D. Savage,, J. W. Drijfhout,, D. R. Flower,, W. A. Hanekom,, M. R. Klein,, and T. H. Ottenhoff. 2010. Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathog. 6: e1000782.
81. Jouanguy, E.,, F. Altare,, S. Lamhamedi,, P. Revy,, J. F. Emile,, M. Newport,, M. Levin,, S. Blanche,, E. Seboun,, A. Fischer,, J. L. Casanova,, E. Jouanguy,, F. Altare,, S. Lamhamedi,, P. Revy,, J. F. Emile,, M. Newport,, M. Levin,, S. Blanche,, E. Seboun,, A. Fischer,, and J. L. Casanova. 1996. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N. Engl. J. Med. 335: 19561961.
82. Kallenius, G.,, A. Pawlowski,, P. Brandtzaeg,, and S. Svenson. 2007. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis (Edinburgh) 87: 257266.
83. Karonga Trial Prevention Group. 1996. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 348: 1724.
84. Katila, M. L.,, E. Brander,, and A. Backman. 1987. Neonatal BCG vaccination and mycobacterial cervical adenitis in childhood. Tubercle 68: 291296.
85. Kemp, E. B.,, R. B. Belshe,, and D. F. Hoft. 1996. Immune responses stimulated by percutaneous and intradermal Bacille Calmette-Guerin. J. Infect. Dis. 174: 113119.
86. Khader, S. A.,, J. E. Pearl,, K. Sakamoto,, L. Gilmartin,, G. K. Bell,, D. M. Jelley-Gibbs,, N. Ghilardi,, F. deSauvage,, and A. M. Cooper. 2005. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J. Immunol. 175: 788795.
87. Kristensen, I.,, P. Aaby,, and H. Jensen. 2000. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. BMJ 321: 14351438.
88. Kröger, L.,, M. Korppi,, E. Brander,, H. Kröger,, O. WaszHöckert,, A. Backman,, J. Rapola,, K. Launiala,, and M. Katila. 1995. Osteitis caused by Bacille Calmette-Guérin vaccination: a retrospective analysis of 222 cases. J. Infect. Dis. 172: 574576.
89. Kursar, M.,, M. Koch,, H. W. Mittrucker,, G. Nouailles,, K. Bonhagen,, T. Kamradt,, and S. H. Kaufmann. 2007. Cutting edge: regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J. Immunol. 178: 26612665.
90. Kusner, D. J. 2005. Mechanisms of mycobacterial persistence in tuberculosis. Clin. Immunol. 114: 239247.
91. Lagranderie, M.,, A. M. Balazuc,, M. Abolhassani,, P. Chavarot,, M. A. Nahori,, F. Thouron,, G. Milon,, and G. Marchal. 2002. Development of mixed Th1/Th2 type immune response and protection against Mycobacterium tuberculosis after rectal or subcutaneous immunization of newborn and adult mice with Mycobacterium bovis BCG. Scand. J. Immunol. 55: 293303.
92. Lahey, T.,, R. D. Arbeit,, M. Bakari,, C. R. Horsburgh,, M. Matee,, R. Waddel,, L. Mtei,, J. M. Vuola,, K. Pallangyo,, and C. F. von Reyn. 2010. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine 28: 76527658.
93. Lalor, M. K.,, S. G. Smith,, S. Floyd,, P. Gorak-Stolinska,, R. E. Weir,, R. Blitz,, K. Branson,, P. E. Fine,, and H. M. Dockrell. 2010. Complex cytokine profiles induced by BCG vaccination in UK infants. Vaccine 28: 16351641.
94. Lambert, P. H.,, T. Hawkridge,, and W. A. Hanekom. 2009. New vaccines against tuberculosis. Clin. Chest Med. 30: 811826, x.
95. Langermans, J. A.,, P. Andersen,, D. van Soolingen,, R. A. Vervenne,, P. A. Frost,, T. van der Laan,, L. A. van Pinxteren,, J. van den Hombergh,, S. Kroon,, I. Peekel,, S. Florquin,, and A. W. Thomas. 2001. Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proc. Natl. Acad. Sci. USA 98: 1149711502.
96. Leroy, H.,, C. Arvieux,, J. Biziragusenyuka,, J. M. Chapplain,, C. Guiguen,, C. Michelet,, and P. Tattevin. 2008. A retrospective study of 230 consecutive patients hospitalized for presumed travel-related illness (2000–2006). Eur. J. Clin. Microbiol. Infect. Dis. 27: 11371140.
97. Leung, C. C.,, C. M. Tam,, S. L. Chan,, M. Chan-Yeung,, C. K. Chan,, and K. C. Chang. 2001. Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong. Int. J. Tuberc. Lung Dis. 5: 717723.
98. Levine, M. I.,, and M. F. Sackett. 1948. Results of BCG immunization in New York City. Am. Rev. Tuberc. 53: 517532.
99. Lewinsohn, D. A.,, E. Winata,, G. M. Swarbrick,, K. E. Tanner,, M. S. Cook,, M. D. Null,, M. E. Cansler,, A. Sette,, J. Sidney,, and D. M. Lewinsohn. 2007. Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog. 3: 12401249.
100. Lewinsohn, D. M.,, A. L. Briden,, S. G. Reed,, K. H. Grabstein,, and M. R. Alderson. 2000. Mycobacterium tuberculosis-reactive CD8+ T lymphocytes: the relative contribution of classical versus nonclassical HLA restriction. J. Immunol. 165: 925930.
101. Liu, P. T.,, S. Stenger,, H. Li,, L. Wenzel,, B. H. Tan,, S. R. Krutzik,, M. T. Ochoa,, J. Schauber,, K. Wu,, C. Meinken,, D. L. Kamen,, M. Wagner,, R. Bals,, A. Steinmeyer,, U. Zugel,, R. L. Gallo,, D. Eisenberg,, M. Hewison,, B. W. Hollis,, J. S. Adams,, B. R. Bloom,, and R. L. Modlin. 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 17701773.
102. Lopez de Castilla, D.,, and N. W. Schluger. 2009. Tuberculosis following solid organ transplantation. Transpl. Infect. Dis. 12: 106112.
103. Lotte, A.,, O. Wasz-Hockert,, N. Poisson,, N. Dumitrescu,, M. Verron,, and E. Couvet. 1984. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv. Tuberc. Res. 21: 107193.
104. Lotte, A.,, O. Wasz-Hockert,, N. Poisson,, H. Engbaek,, H. Landmann,, U. Quast,, B. Andrasofszky,, L. Lugosi,, I. Vadasz,, and P. Mihailescu. 1988. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull. Int. Union Tuberc. Lung Dis. 63: 4759.
105. Lowry, P. W.,, T. S. Ludwig,, J. A. Adams,, M. L. Fitzpatrick,, S. M. Grant,, G. A. Andrle,, M. R. Offerdahl,, S. Cho,, and D. R. Jacobs. 1998. Cellular immune responses to four doses of percutaneous Bacille Calmette-Guérin in healthy adults. J. Infect. Dis. 178: 138146.
106. Lowry, P. W.,, T. S. Ludwig,, J. A. Adams,, M. L. Fitzpatrick,, S. M. Grant,, G. A. Andrle,, M. R. Offerdahl,, S. N. Cho,, and D. R. Jacobs, Jr. 1998. Cellular immune responses to four doses of percutaneous bacille Calmette-Guerin in healthy adults. J. Infect. Dis. 178: 138146.
107. Magalhaes, I.,, D. R. Sizemore,, R. K. Ahmed,, S. Mueller,, L. Wehlin,, C. Scanga,, F. Weichold,, G. Schirru,, M. G. Pau,, J. Goudsmit,, S. Kuhlmann-Berenzon,, M. Spangberg,, J. Anders-son,, H. Gaines,, R. Thorstensson,, Y. A. Skeiky,, J. Sadoff,, and M. Maeurer. 2008. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One 3: e3790.
108. Manabe, Y. C.,, C. P. Scott,, and W. R. Bishai. 2002. Naturally attenuated, orally administered Mycobacterium microti as a tuberculosis vaccine is better than subcutaneous Mycobacterium bovis BCG. Infect. Immun. 70: 15661570.
109. Mansoor, N.,, T. J. Scriba,, M. de Kock,, M. Tameris,, B. Abel,, A. Keyser,, F. Little,, A. Soares,, S. Gelderbloem,, S. Mlenjeni,, L. Denation,, A. Hawkridge,, W. H. Boom,, G. Kaplan,, G. D. Hussey,, and W. A. Hanekom. 2009. HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guerin vaccine. J. Infect. Dis. 199: 982990.
110. Marchant, A.,, T. Goetghebuer,, M. O. Ota, et al. 1999. Newborns develop a Th1-type immune response to Mycobacterium bovis Bacillus Calmette-Guerin vaccination. J. Immunol. 163: 22492255.
111. Marsh, B. J.,, C. F. von Reyn,, J. Edwards,, M. A. Ristola,, C. Bartholomew,, R. J. Brindle,, C. F. Gilks,, R. W. Waddell,, A. N. Tosteson,, R. Peltz,, C. H. Sox,, R. Frothingham,, R. D. Arbeit, and International MAC Study Group. 1997. The risks and benefits of childhood bacille Calmette-Guerin immunization among adults with AIDS. AIDS 11: 669672.
112. Matee, M.,, T. Lahey,, J. M. Vuola,, L. Mtei,, B. F. Cole,, M. Bakari,, R. D. Arbeit,, C. R. Horsburgh,, K. Pallangyo,, and C. F. von Reyn. 2007. Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guerin during childhood and entering a tuberculosis booster vaccine trial. J. Infect. Dis. 195: 118123.
113. McKinney, J. D.,, K. Honer zu Bentrup,, E. J. Munoz-Elias,, A. Miczak,, B. Chen,, W. T. Chan,, D. Swenson,, J. C. Sacchettini,, W. R. Jacobs, Jr.,, and D. G. Russell. 2000. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406: 735738.
114. McMurray, D. N. 1981. Cellular immune changes in undernourished children. Prog. Clin. Biol. Res. 67: 305318.
115. Modi, S.,, A. M. Buff,, C. J. Lawson,, D. Rodriguez,, H. L. Kirking,, H. Lipman,, and D. B. Fishbein. 2009. Reporting patterns and characteristics of tuberculosis among international travelers, United States, June 2006 to May 2008. Clin. Infect. Dis. 49: 885891.
116. Mogues, T.,, M. E. Goodrich,, L. Ryan,, R. LaCourse,, and R. J. North. 2001. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J. Exp. Med. 193: 271280.
117. Mohan, A. K.,, T. R. Cote,, J. A. Block,, A. M. Manadan,, J. N. Siegel,, and M. M. Braun. 2004. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin. Infect. Dis. 39: 295299.
118. Morais Fonseca, D.,, R. S. Rosada,, M. Oliveira e Paula,, P. F. Wowk,, L. H. Franco,, E. G. Soares,, C. L. Silva,, and V. L. Deperon Bonato. 2010. Experimental tuberculosis: designing a better model to test vaccines against tuberculosis. Tuberculosis (Edinburgh) 90: 135142.
119. Narayanan, P. R. 2006. Influence of sex, age & nontuberculous infection at intake on the efficacy of BCG: re-analysis of 15-year data from a double-blind randomized control trial in South India. Indian J. Med. Res. 123: 119124.
120. Ninane, J.,, A. Grymonprez,, G. Burtonboy,, A. Francois,, and G. Cornu. 1988. Disseminated BCG in HIV infection. Arch. Dis. Child. 63: 12681269.
121. Olsen, A. W.,, A. Williams,, L. M. Okkels,, G. Hatch,, and P. Andersen. 2004. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72: 61486150.
122. Opie, E. L.,, E. W. Flahiff,, and H. H. Smith. 1939. Protective inoculation against human tuberculosis with heat-killed tubercle bacilli. Am. J. Hyg. 29: 155164.
123. Orme, I. M.,, D. N. McMurray,, and J. T. Belisle. 2001. Tuberculosis vaccine development: recent progress. Trends Microbiol. 9: 115118.
124. Portaels, F.,, J. Aguiar,, M. Debacker,, A. Guedenon,, C. Steunou,, C. Zinsou,, and W. M. Meyers. 2004. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect. Immun. 72: 6265.
125. Praveen, K. N.,, M. F. Smikle,, P. Prabhakar,, D. Pande,, B. Johnson,, and D. Ashley. 1990. Outbreak of Bacillus Calmette-Guerin-associated lymphadenitis and abscesses in Jamaican children. Pediatr. Infect. Dis. J. 9: 890893.
126. Radosevic, K.,, C. W. Wieland,, A. Rodriguez,, G. J. Weverling,, R. Mintardjo,, G. Gillissen,, R. Vogels,, Y. A. Skeiky,, D. M. Hone,, J. C. Sadoff,, T. van der Poll,, M. Havenga,, and J. Goudsmit. 2007. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect. Immun. 75: 41054115.
127. Ravn, P.,, H. Boesen,, and B. K. Pedersen. 1997. Human T cell responses induced by vaccination with Mycobacterium bovis Bacillus Calmette-Guerin. J. Immunol. 158: 19491955.
128. Reed, S. G.,, R. N. Coler,, W. Dalemans,, E. V. Tan,, E. C. DeLa Cruz,, R. J. Basaraba,, I. M. Orme,, Y. A. Skeiky,, M. R. Alder-son,, K. D. Cowgill,, J. P. Prieels,, R. M. Abalos,, M. C. Dubois,, J. Cohen,, P. Mettens,, and Y. Lobet. 2009. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc. Natl. Acad. Sci. USA 106: 23012306.
129. Rodrigues, L. C.,, V. K. Diwan,, and J. G. Wheeler. 1993. Protective effect of BCG against tuberculosis meningitis and miliary tuberculosis: a meta-analysis. Int. J. Epidemiol. 22: 11541158.
130. Rodrigues, L. C.,, S. M. Pereira,, S. S. Cunha,, B. Genser,, M. Y. Ichihara,, S. C. de Brito,, M. A. Hijjar,, I. Dourado,, A. A. Cruz,, C. Sant’Anna,, A. L. Bierrenbach,, and M. L. Barreto. 2005. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 366: 12901295.
131. Romanus, V.,, H. H. Hallander,, P. Wahlen,, A. M. Olinder-Nielsen,, P. H. W. Magnusson,, and I. Juhlin. 1995. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tuber. Lung Dis. 76: 300310.
132. Romanus, V.,, A. Svensson,, and H. O. Hallander. 1992. The impact of changing BCG coverage on tuberculosis incidence in Swedish born children between 1969 and 1989. Tubercle 73: 150161.
133. Rosenthal, S. R.,, E. Loewinsohn,, M. L. Graham,, D. Liveright,, M. G. Thorne,, and V. Johnson. 1960. BCG vaccination in tuberculous households. Am. Rev. Respir. Dis. 84: 690704.
134. Rosenthal, S. R.,, E. Loewinsohn,, M. L. Graham,, D. Liveright,, M. G. Thorne,, V. Johnson,, and H. C. Batson. 1961. BCG vaccination against tuberculosis in Chicago: a twenty year study statistically analyzed. Pediatrics 28: 622641.
135. Rota, S.,, U. Beyazova,, T. Karsligil,, and C. Cevheroglu. 1994. Humoral immune response against antigen 60 in BCG-vaccinated infants. Eur. J. Epidemiol. 10: 713718.
136. Roth, A.,, H. Jensen,, M. L. Garly,, Q. Djana,, C. L. Martins,, M. Sodemann,, A. Rodrigues,, and P. Aaby. 2004. Low birth weight infants and Calmette-Guerin bacillus vaccination at birth: community study from Guinea-Bissau. Pediatr. Infect. Dis. J. 23: 544550.
137. Sakula, A. 1983. BCG: who were Calmette and Guerin? Thorax 38: 806812.
138. Salo, E. P. 2006. BCG in Finland: changing from a universal to a selected programme. Eur. Surveill. 11: 1820.
139. Sander, C. R.,, A. A. Pathan,, N. E. Beveridge,, I. Poulton,, A. Minassian,, N. Alder,, J. Van Wijgerden,, A. V. Hill,, F. V. Gleeson,, R. J. Davies,, G. Pasvol,, and H. McShane. 2009. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am. J. Respir. Crit. Care Med. 179: 724733.
140. Scriba, T. J.,, M. Tameris,, N. Mansoor,, E. Smit,, L. van der Merwe,, F. Isaacs,, A. Keyser,, S. Moyo,, N. Brittain,, A. Lawrie,, S. Gelderbloem,, A. Veldsman,, M. Hatherill,, A. Hawkridge,, A. V. Hill,, G. D. Hussey,, H. Mahomed,, H. McShane,, and W. A. Hanekom. 2010. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4 + T cells. Eur. J. Immunol. 40: 279290.
141. Shelley, M. D.,, T. J. Wilt,, J. Court,, B. Coles,, H. Kynaston,, and M. D. Mason. 2004. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 93: 485490.
142. Skeiky, Y. A.,, and J. C. Sadoff. 2006. Advances in tuberculosis vaccine strategies. Nat. Rev. Microbiol. 4: 469476.
143. Smith, K. C.,, and J. R. Starke. 1999. Bacille Calmette Guerin vaccine, p. 121. In S. A. Plotkin and, W. A. Orenstein (ed.), Vaccines. W. B. Saunders, Philadelphia, PA.
144. Smith, P. G.,, W. D. Revill,, E. Lukwago,, and Y. P. Rykushin. 1977. The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans. R. Soc. Trop. Med. Hyg. 70: 449457.
145. Soares, A. P.,, T. J. Scriba,, S. Joseph,, R. Harbacheuski,, R. A. Murray,, S. J. Gelderbloem,, A. Hawkridge,, G. D. Hussey,, H. Maecker,, G. Kaplan,, and W. A. Hanekom. 2008. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J. Immunol. 180: 35693577.
146. Sonnenberg, P.,, J. Murray,, J. R. Glynn,, S. Shearer,, B. Kambashi,, and P. Godfrey-Faussett. 2001. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358: 16871693.
147. Soysal, A.,, K. A. Millington,, M. Bakir,, D. Dosanjh,, Y. Aslan,, J. J. Deeks,, S. Efe,, I. Staveley,, K. Ewer,, and A. Lalvani. 2005. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366: 14431451.
148. Starke, J. R. 2001. Transmission of Mycobacterium tuberculosis to and from children and adolescents. Semin. Pediatr. Infect. Dis. 12: 115.
149. Stead, W. W.,, and A. K. Dutt. 1989. Tuberculosis in the elderly. Semin. Respir. Infect. 4: 189197.
150. Stead, W. W.,, J. P. Lofgren,, E. Warren,, and C. Thomas. 1985. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N. Engl. J. Med. 312: 14831487.
151. Stein, S. C.,, and J. D. Aronson. 1953. The occurrence of pulmonary lesions in BCG vaccinated and unvacccinated persons. Am. Rev. Tuberc. 68: 692712.
152. Surekha Rani, H.,, V. Vijaya Lakshmi,, G. Sumanlatha,, and K. J. Murthy. 2005. Cell-mediated immune responses in children towards secreted proteins of Mycobacterium bovis BCG. Tuberculosis (Edinburgh) 85: 8993.
153. Tala, E.,, V. Romanus,, and M. Tala-Heikkilä. 1997. Bacille Calmette-Guérin vaccination in the 21st century. Eur. Respir. Mon. 4: 327353.
154. Talbot, E. A.,, M. D. Perkins,, S. F. Silva,, and R. Frothingham. 1997. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin. Infect. Dis. 24: 11391146.
155. Tanaka, Y.,, C. T. Morita,, E. Nieves,, M. B. Brenner,, and B. R. Bloom. 1995. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375: 155158.
156. Thoma-Uszynski, S.,, S. Stenger,, O. Takeuchi,, M. T. Ochoa,, M. Engele,, P. A. Sieling,, P. F. Barnes,, M. Rollinghoff,, P. L. Bolcskei,, M. Wagner,, S. Akira,, M. V. Norgard,, J. T. Belisle,, P. J. Godowski,, B. R. Bloom,, and R. L. Modlin. 2001. Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science 291: 15441547.
157. Tompkins, D. M.,, D. S. Ramsey,, M. L. Cross,, F. E. Aldwell,, G. W. de Lisle,, and B. M. Buddle. 2009. Oral vaccination reduces the incidence of tuberculosis in free-living brushtail possums. Proc. Biol. Sci. 276: 29872995.
158. Trevenen, C. L.,, and R. D. Pagtakhan. 1982. Disseminated tuberculoid lesions in infants following BCG vaccination. Can. Med. Assoc. J. 127: 502504.
159. Tsenova, L.,, R. Harbacheuski,, A. L. Moreira,, E. Ellison,, W. Dalemans,, M. R. Alderson,, B. Mathema,, S. G. Reed,, Y. A. Skeiky,, and G. Kaplan. 2006. Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect. Immun. 74: 23922401.
160. Tuberculosis Prevention Trial, Madras. 1980. Trial of BCG vaccines in South India for tuberculosis prevention. Indian J. Med. Res. 72 (Suppl.): 174.
161. Turnbull, F. M.,, P. B. McIntyre,, H. M. Achat,, H. Wang,, R. Stapledon,, M. Gold,, and M. A. Burgess. 2002. National study of adverse reactions after vaccination with Bacille Calmette-Guerin. Clin. Infect. Dis. 34: 447453.
162. Turneer, M.,, J. P. Van Vooren,, J. Nyabenda,, F. Legros,, A. Lecomte,, J. Thiriaux,, E. Serruys,, and J. C. Yernault. 1988. The humoral immune response after BCG vaccination in humans: consequences for the serodiagnosis of tuberculosis. Eur. Respir. J. 1: 589593.
163. Ulrichs, T.,, D. B. Moody,, E. Grant,, S. H. Kaufmann,, and S. A. Porcelli. 2003. T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection. Infect. Immun. 71: 30763087.
164. Vandiviere, H. M.,, M. Dworski,, I. G. Melvin,, K. A. Watson,, and J. Begley. 1973. Efficacy of bacillus Calmette-Guerin and isoniazid-resistant bacillus Calmette-Guerin with and without isoniazid chemoprophylaxis from day of vaccination. II. Field trial in man. Am. Rev. Respir. Dis. 108: 301313.
165. Vipond, J.,, M. L. Cross,, M. R. Lambeth,, S. Clark,, F. E. Ald well,, and A. Williams. 2008. Immunogenicity of orally-delivered lipid-formulated BCG vaccines and protection against Mycobacterium tuberculosis infection. Microbes Infect. 10: 15771581.
166. von Reyn, C. F. 1999. The significance of bacteremic tuberculosis among persons with HIV infection in developing countries. AIDS 13: 21932195.
167. von Reyn, C. F.,, T. W. Barber,, R. D. Arbeit,, C. H. Sox,, G. T. O’Connor,, R. J. Brindle,, C. F. Gilks,, K. Hakkarainen,, A. Ranki,, C. Bartholomew,, A. N. A. Tosteson,, and M. Magnusson. 1993. Evidence of previous infection with M. avium among healthy subjects: an international study of dominant mycobacterial skin test reactions. J. Infect. Dis. 168: 15531558.
168. von Reyn, C. F.,, C. R. Horsburgh,, K. N. Olivier,, P. F. Barnes,, R. Waddell,, C. Warren,, S. Tvaroha,, A. S. Jaeger,, A. D. Lein,, R. Alexander,, D. J. Weber,, and A. N. Tosteson. 2001. Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int. J. Tuberc. Lung Dis. 5: 11221128.
169. von Reyn, C. F.,, L. Mtei,, R. D. Arbeit,, R. Waddell,, B. Cole,, T. Mackenzie,, M. Matee,, M. Bakari,, S. Tvaroha,, L. V. Adams,, C. R. Horsburgh,, and K. Pallangyo. 2010. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24: 675685.
170. von Reyn, C. F.,, and J. Vuola. 2002. New vaccines for the prevention of tuberculosis. Clin. Infect. Dis. 35: 465474.
171. von Reyn, C. F.,, P. Williams,, H. Lederman,, J. A. McCutchan,, S. L. Koletar,, R. L. Murphy,, S. E. Cohn,, T. Evans,, A. E. Heald,, D. Colquhoun,, E. L. Bassily,, and J. S. Currier. 2001. Skin test reactivity and cellular immune responses to Mycobacterium avium sensitin in AIDS patients at risk for disseminated M. avium infection. Clin. Diagn. Lab. Immunol. 8: 12771278.
172. Vuola, J. M.,, M. A. Ristola,, B. Cole,, A. Jarviluoma,, S. Tvaroha,, T. Ronkko,, O. Rautio,, R. D. Arbeit,, and C. F. Reyn. 2003. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS 17: 23512355.
173. Waddell, R. D.,, C. Chintu,, A. D. Lein,, A. Zumla,, M. R. Karagas,, K. S. Baboo,, J. D. F. Habbema,, A. N. A. Tosteson,, P. Morin,, S. Tvaroha,, R. D. Arbeit,, A. Mwinga,, and C. F. von Reyn. 2000. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin. Infect. Dis. 30 (Suppl. 3): S309S315.
174. Waddell, R. D.,, K. Lishimpi,, C. F. von Reyn,, C. Chintu,, K. S. Baboo,, B. Kreiswirth,, E. Talbot,, M. R. Karagas, and Dart-mouth/UCLMS/UNZA Collaborative Study Group. 2001. Bacteremia due to Mycobacterium tuberculosis or M. bovis, Bacille Calmette-Guerin (BCG) among HIV-positive children and adults in Zambia. AIDS 15: 5560.
175. Walls, T.,, and D. Shingadia. 2004. Global epidemiology of paediatric tuberculosis. J. Infect. 48: 1322.
176. Weiss, D. W. 1959. Vaccination against tuberculosis with non-living vaccines. I. The problem and its historical background. Am. Rev. Respir. Dis. 80: 676688.
177. Whelan, K. T.,, A. A. Pathan,, C. R. Sander,, H. A. Fletcher,, I. Poulton,, N. C. Alder,, A. V. Hill,, and H. McShane. 2009. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS One 4: e5934.
178. Wilkinson, K. A.,, R. Seldon,, G. Meintjes,, M. X. Rangaka,, W. A. Hanekom,, G. Maartens,, and R. J. Wilkinson. 2009. Dissection of regenerating T-cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 180: 674683.
179. World Health Organization. 2009. Global Tuberculosis Control: a Short Update to the 2009 Report. World Health Organization, Geneva, Switzerland.
180. World Health Organization. 2010. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. World Health Organization, Geneva, Switzerland.
181. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. 1995. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. J. Infect. Dis. 171: 10971106.
182. Xu, Y.,, C. Jagannath,, X. D. Liu,, A. Sharafkhaneh,, K. E. Kolodziejska,, and N. T. Eissa. 2007. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 27: 135144.
183. Yuen, K. Y.,, and P. C. Woo. 2002. Tuberculosis in blood and marrow transplant recipients. Hematol. Oncol. 20: 5162.
184. Zar, H. J.,, M. F. Cotton,, S. Strauss,, J. Karpakis,, G. Hussey,, H. S. Schaaf,, H. Rabie,, and C. J. Lombard. 2007. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 334: 136.
185. Ziegler, J. E.,, M. L. Edwards,, and D. W. Smith. 1985. Exogenous reinfection in experimental airborne tuberculosis. Tubercle 66: 121128.


Generic image for table
Table 1.

Known sources of protection against tuberculosis in humans

Citation: Lahey T, Reyn C. 2011. BCG and New Vaccines against Tuberculosis, p 162-181. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817138.ch10
Generic image for table
Table 2.

Efficacy of BCG against tuberculosis: trials in newborns

Citation: Lahey T, Reyn C. 2011. BCG and New Vaccines against Tuberculosis, p 162-181. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817138.ch10
Generic image for table
Table 3.

Efficacy of BCG against tuberculosis: trials meeting strict methodologic criteria

Citation: Lahey T, Reyn C. 2011. BCG and New Vaccines against Tuberculosis, p 162-181. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817138.ch10
Generic image for table
Table 4.

Adverse effects of parenteral BCG immunization

Citation: Lahey T, Reyn C. 2011. BCG and New Vaccines against Tuberculosis, p 162-181. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817138.ch10
Generic image for table
Table 5.

Recommendations for BCG use in the United States

Citation: Lahey T, Reyn C. 2011. BCG and New Vaccines against Tuberculosis, p 162-181. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817138.ch10
Generic image for table
Table 6.

Characteristics of BCG

Citation: Lahey T, Reyn C. 2011. BCG and New Vaccines against Tuberculosis, p 162-181. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817138.ch10
Generic image for table
Table 7.

Selected promising tuberculosis candidate vaccines

Citation: Lahey T, Reyn C. 2011. BCG and New Vaccines against Tuberculosis, p 162-181. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817138.ch10

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error